Nature Biotechnology
- 24, 1377 - 1383 (2006)
Published online: 8 November 2006; | doi:10.1038/nbt1261
Vaccine manufacturing: challenges and solutionsJeffrey B Ulmer1, Ulrich Valley2 & Rino Rappuoli31
Novartis Vaccines and Diagnostics, 4560 Horton St., Mailstop 4.3, Emeryville, California 94608, USA. 2
Novartis Vaccines and Diagnostics, GmbH & Co. KG, Emil von Behring Strasse 76, D-35041 Marburg, Germany. 3
Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina No. 1, I-53100, Siena, Italy.
Correspondence should be addressed to Jeffrey B Ulmer jeffrey_ulmer@chiron.com The recent influenza vaccine shortages have provided a timely reminder of the tenuous nature of the world's vaccine supply and the potential for manufacturing issues to severely disrupt vital access to important vaccines. The application of new technologies to the discovery, assessment, development and production of vaccines has the potential to prevent such occurrences and enable the introduction of new vaccines. Gene-based vaccines, virus-like particles, plant-derived vaccines and novel adjuvants and delivery systems represent promising approaches to creating safer, more potent vaccines. As a consequence, more people will have faster access to more effective vaccines against a broader spectrum of infectious diseases. However, the increased cost of producing new vaccines and regulatory uncertainty remain challenges for vaccine manufacturers.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
